Approval · Notice of Compliance 25950 · 2021
DIVALPROEX: Notice of Compliance 25950
Issued May 27, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25950
- Date
- May 27, 2021
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- Change in product ownership
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIVALPROEX | 02239517 | Approved |
| DIVALPROEX | 02239518 | Approved |
| DIVALPROEX | 02239519 | Approved |
Medicinal ingredients
- VALPROIC ACID 125 MG per TAB
- VALPROIC ACID 250 MG per TAB
- VALPROIC ACID 500 MG per TAB